SCHEMBL699261

SCHEMBL699261

Cc1nc2ccccn2c1-c1ccnc(Nc2ccc(C(=O)Nc3ccccc3N)cc2F)n1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 8/20 0.71
CDK2 P24941 9/20 0.58
CDK4 P11802 5/20 0.58
CCNE1 P24864 4/20 0.58
IGF1R P08069 3/20 0.49
PLK4 O00444 1/20 0.48
CHEK1 O14757 1/20 0.48
AURKA O14965 1/20 0.48
DAPK3 O43293 1/20 0.48
ROCK2 O75116 1/20 0.48
PRKD3 O94806 1/20 0.48
MAP4K4 O95819 1/20 0.48
PAK4 O96013 1/20 0.48
CHEK2 O96017 1/20 0.48
EGFR P00533 1/20 0.48
ERBB2 P04626 1/20 0.48
NTRK1 P04629 1/20 0.48
PRKCG P05129 1/20 0.48
INSR P06213 1/20 0.48
LCK P06239 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL699844 0.89 HDAC1 (0.59) HDAC1CDK2CDK4CCNE1IGF1R
SCHEMBL699145 0.88 HDAC1 (0.79) HDAC1CDK2CDK4CCNE1
SCHEMBL10252006 0.88 CDK2 (0.62) HDAC1CDK2CDK4CCNE1IGF1R
SCHEMBL699906 0.88 HDAC1 (0.70) HDAC1CDK2CDK4CCNE1IGF1R
SCHEMBL7978108 0.87 CDK2 (0.62) HDAC1CDK2CDK4CCNE1IGF1R
SCHEMBL699927 0.86 HDAC1 (0.72) HDAC1CDK2CDK4CCNE1
SCHEMBL7980888 0.85 CDK2 (0.59) HDAC1CDK2CDK4CCNE1IGF1R
SCHEMBL699278 0.85 HDAC1 (0.64) HDAC1CDK2CDK4CCNE1IGF1R
SCHEMBL700158 0.85 HDAC1 (0.68) HDAC1CDK2CDK4CCNE1
SCHEMBL12790485 0.84 HDAC1 (0.54) HDAC1CDK2CDK4CCNE1PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124764-B2 Fused heterocyclyc inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-02-28 US claimed
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-02-04 US claimed
US-8124764-B2 Fused heterocyclyc inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-02-28 US disclosed
US-8124764-B2 Fused heterocyclyc inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-02-28 US disclosed
US-8124764-B2 Fused heterocyclyc inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-02-28 US disclosed
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-02-04 US disclosed
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-02-04 US disclosed
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-02-04 US disclosed
WO-2010009155-A2 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD COLORADO, INC. (US) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC7 HDAC1 1/4885CDK2 16/4885CDK4 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.